Science and Research

Unsupervised clustering algorithms improve the reproducibility of dynamic contrast-enhanced magnetic resonance imaging pulmonary perfusion quantification in muco-obstructive lung diseases

BACKGROUND: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) allows the assessment of pulmonary perfusion, which may play a key role in the development of muco-obstructive lung disease. One problem with quantifying pulmonary perfusion is the high variability of metrics. Quantifying the extent of abnormalities using unsupervised clustering algorithms in residue function maps leads to intrinsic normalization and could reduce variability. PURPOSE: We investigated the reproducibility of perfusion defects in percent (QDP) in clinically stable patients with cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). METHODS: 15 CF (29.3 ± 9.3y, FEV1%predicted = 66.6 ± 15.8%) and 20 COPD (66.5 ± 8.9y, FEV1%predicted = 42.0 ± 13.3%) patients underwent DCE-MRI twice 1 month apart. QDP, pulmonary blood flow (PBF), and pulmonary blood volume (PBV) were computed from residue function maps using an in-house quantification pipeline. A previously validated MRI perfusion score was visually assessed by an expert reader. RESULTS: Overall, mean QDP, PBF, and PBV did not change within 1 month, except for QDP in COPD (p < 0.05). We observed smaller limits of agreement (± 1.96 SD) related to the median for QDP (CF: ± 38%, COPD: ± 37%) compared to PBF (CF: ± 89%, COPD: ± 55%) and PBV (CF: ± 55%, COPD: ± 51%). QDP correlated moderately with the MRI perfusion score in CF (r = 0.46, p < 0.05) and COPD (r = 0.66, p < 0.001). PBF and PBV correlated poorly with the MRI perfusion score in CF (r =-0.29, p = 0.132 and r =-0.35, p = 0.067, respectively) and moderately in COPD (r =-0.57 and r =-0.57, p < 0.001, respectively). CONCLUSION: In patients with muco-obstructive lung diseases, QDP was more robust and showed a higher correlation with the MRI perfusion score compared to the traditionally used perfusion metrics PBF and PBV.
  • Konietzke, M.
  • Triphan, S. M. F.
  • Eichinger, M.
  • Bossert, S.
  • Heller, H.
  • Wege, S.
  • Eberhardt, R.
  • Puderbach, M. U.
  • Kauczor, H. U.
  • Heußel, G.
  • Heußel, C. P.
  • Risse, F.
  • Wielpütz, M. O.

Keywords

  • chronic obstructive pulmonary disease (COPD)
  • contrast agent lung perfusion
  • cystic fibrosis (CF)
  • functional imaging
  • muco-obstructive lung disease
Publication details
DOI: 10.3389/fmed.2022.1022981
Journal: Front Med (Lausanne)
Pages: 1022981 
Work Type: Original
Location: TLRC
Disease Area: CFBE, COPD, PLI
Partner / Member: UKHD
Access-Number: 36353218

DZL Engagements

chevron-down